KEITH M GOTTESDIENER
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
- Where
- RAHWAY, NJ
- NPI
- 1821150376
- Received
- $2,131,252 in 99 records, 2019 to 2025; ownership interests with $767,059 invested
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 1 | $21,500 |
| 2024 | General payment | 5 | $115,550 |
| 2023 | General payment | 16 | $639,947 |
| 2023 | Ownership or investment interest | 2 | $264,454 |
| 2022 | General payment | 15 | $335,000 |
| 2022 | Ownership or investment interest | 2 | $262,384 |
| 2021 | General payment | 16 | $356,722 |
| 2021 | Ownership or investment interest | 2 | $240,219 |
| 2020 | General payment | 17 | $331,189 |
| 2020 | Ownership or investment interest | 2 | $0 |
| 2019 | General payment | 19 | $331,343 |
| 2019 | Ownership or investment interest | 2 | $0 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,585,573 | 2019–2025 |
| Intercept Pharmaceuticals, Inc. | 31 | $1,312,537 | 2019–2023 |
| Novo Nordisk AS | 1 | $104 | 2019 |
| EMD Serono, Inc. | 1 | $96 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 80 | $2,121,543 |
| Ownership or investment interest | 10 | $767,059 |
| Travel and Lodging | 6 | $9,433 |
| Food and Beverage | 3 | $275 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-05-23 | Takeda Pharmaceuticals U.S.A., Inc. | $21,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $15,550 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-04-03 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-03 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2023-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-01 | Intercept Pharmaceuticals, Inc. | $328,539 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2023 | |
| 2023-11-16 | Intercept Pharmaceuticals, Inc. | $6,333 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2023 | |
| 2023-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-20 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2023 | |
| 2023-10-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-16 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-21 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2023 | |
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $74 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-12 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-04-07 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-22 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-25 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2022-12-14 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-23 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-01 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-17 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-22 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2022 | |
| 2022-07-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-22 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-16 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-13 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2022 | |
| 2022-04-07 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-03-14 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-24 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-01 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2022 | |
| 2022-01-27 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2021-12-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-05 | Intercept Pharmaceuticals, Inc. | $15,000 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2021 | |
| 2021-09-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-16 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-26 | Intercept Pharmaceuticals, Inc. | $14,222 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2021 | |
| 2021-07-17 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-05-18 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-04-26 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2021 | |
| 2021-03-24 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-22 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-02-22 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-02-02 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2021 | |
| 2021-01-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2020-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Takeda Pharmaceuticals U.S.A., Inc. | $549 | Travel and Lodging | In-kind items and services | 2020 | ||
| 2020-10-27 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-15 | Intercept Pharmaceuticals, Inc. | $639 | Travel and Lodging | Cash or cash equivalent | 2020 | ||
| 2020-08-21 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-08-05 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-23 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-06-03 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-05-26 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-04-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-03-27 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-02-24 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-01-24 | Intercept Pharmaceuticals, Inc. | $13,750 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2019-12-23 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-11-25 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-11-22 | Intercept Pharmaceuticals, Inc. | $855 | Travel and Lodging | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2019 | |
| 2019-10-26 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-09-26 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-09-01 | Intercept Pharmaceuticals, Inc. | $1,468 | Travel and Lodging | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2019 | |
| 2019-08-26 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-07-25 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-06-14 | Intercept Pharmaceuticals, Inc. | $4,497 | Travel and Lodging | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2019 | |
| 2019-06-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-06-04 | Novo Nordisk AS | $104 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-27 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-04-27 | Takeda Pharmaceuticals U.S.A., Inc. | $25,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-03-30 | Takeda Pharmaceuticals U.S.A., Inc. | $30,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-03-08 | Intercept Pharmaceuticals, Inc. | $1,422 | Travel and Lodging | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 2019 | |
| 2019-03-05 | Takeda Pharmaceuticals U.S.A., Inc. | $7,899 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-02-27 | Takeda Pharmaceuticals U.S.A., Inc. | $30,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-02-05 | EMD Serono, Inc. | $96 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-01-30 | Takeda Pharmaceuticals U.S.A., Inc. | $30,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| Intercept Pharmaceuticals, Inc. | $132,248 interest valued $132,248 | Ownership or investment interest | Physician Covered Recipient | Grant Price $17.08 | 2022 | ||
| Intercept Pharmaceuticals, Inc. | $132,245 interest valued $132,245 | Ownership or investment interest | Physician Covered Recipient | Grant Date Grant Type Grant Price Options Granted Fair Value Total Award Fair Value 05/24/2023 NQ $ 9.17 12,547 $ 10.54 $ 132,245.38 | 2023 | ||
| Intercept Pharmaceuticals, Inc. | $132,209 interest valued $132,209 | Ownership or investment interest | Physician Covered Recipient | Grant Type Grant Price Options Granted Fair Value Total Award Fair Value RSU $ - 8,111 $ 16.30 $ 132,209.30 | 2023 | ||
| Intercept Pharmaceuticals, Inc. | $130,136 interest valued $130,136 | Ownership or investment interest | Physician Covered Recipient | Options Granted RSU 7,737 | 2022 | ||
| Intercept Pharmaceuticals, Inc. | $120,164 interest valued $120,164 | Ownership or investment interest | Physician Covered Recipient | Grant Price $ 17.08 | 2021 | ||
| Intercept Pharmaceuticals, Inc. | $120,055 interest valued $120,055 | Ownership or investment interest | Physician Covered Recipient | Options Granted RSU 7,029 | 2021 | ||
| Intercept Pharmaceuticals, Inc. | $0 interest valued $132,253 | Ownership or investment interest | Physician Covered Recipient | Stock Options granted 2,966 on May 28, 2020. | 2020 | ||
| Intercept Pharmaceuticals, Inc. | $0 interest valued $129,132 | Ownership or investment interest | Physician Covered Recipient | Restricted Stock Units (RSU): 1,570. RSU granted on June 20, 2019 | 2019 | ||
| Intercept Pharmaceuticals, Inc. | $0 interest valued $116,020 | Ownership or investment interest | Physician Covered Recipient | RSU granted 1595 on May 28, 2020. | 2020 | ||
| Intercept Pharmaceuticals, Inc. | $0 interest valued $132,222 | Ownership or investment interest | Physician Covered Recipient | Stock Options Granted 2174. Granted on June 20, 2019. | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rahway, NJ, county Union County, NJ, state New Jersey; placed by its city name.
| Measure | Place (city or town) Rahway, NJ | County Union County, NJ | State New Jersey |
|---|---|---|---|
| Population B01003 | 30,109 | 579,290 | 9,343,809 |
| Population, 2020 census P1 | 29,556 | 575,345 | 9,288,994 |
| Median age B01002 | 39.7 | 39.1 | 40.1 |
| Under 18 B01001 | 19.3% | 23.5% | 21.8% |
| 65 and over B01001 | 18.2% | 15.1% | 17.2% |
| Households B11001 | 12,257 | 203,277 | 3,507,701 |
| Foreign born B05002 | 24.0% | 33.6% | 23.9% |
| Median household income B19013 | $91,461 | $103,202 | $103,556 |
| Median family income B19113 | $110,407 | $125,330 | $127,025 |
| Per capita income B19301 | $43,170 | $52,874 | $54,253 |
| Poverty rate B17001 | 9.5% | 9.2% | 9.7% |
| Unemployment rate B23025 | 7.3% | 6.5% | 6.3% |
| Civilian labor force B23025 | 16,135 | 317,599 | 5,003,179 |
| Mean commute (minutes) B08013 | 31.9 | 30.2 | 30.5 |
| Bachelor's degree or higher B15003 | 34.1% | 38.9% | 43.6% |
| Housing units B25001 | 13,002 | 212,385 | 3,791,354 |
| Owner-occupied B25003 | 51.5% | 57.4% | 63.8% |
| Renters B25003 | 48.5% | 42.6% | 36.2% |
| Median home value B25077 | $386,400 | $529,200 | $454,400 |
| Median gross rent B25064 | $1,845 | $1,730 | $1,720 |
| White, not Hispanic B03002 | 29.3% | 35.4% | 50.9% |
| Black B03002 | 30.8% | 19.1% | 12.2% |
| Hispanic or Latino B03002 | 27.4% | 35.2% | 22.5% |
| Asian B03002 | 5.7% | 5.6% | 10.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rahway, NJ.
Comments